糖化血红蛋白及其之外:KDIGO 2020 糖尿病合并慢性肾脏病管理指南解读
本文解读KDIGO 2020年糖尿病合并慢性肾脏病(CKD)管理指南,强调在血糖管理基础上,SGLT2抑制剂和GLP-1受体激动剂等新治疗可提供器官保护。指南旨在整合新选择与基于高质量证据的现有策略,优化糖尿病合并CKD患者的综合照护。文章聚焦综合管理、血糖监测与目标、降糖治疗及指南发布后的新进展。
要点
- KDIGO 2020指南强调糖尿病合并CKD的综合照护,超越单纯血糖管理。
- SGLT2抑制剂和GLP-1受体激动剂被证实可提供器官保护,而不仅是降糖。
- 指南发布后新证据拓展了新干预措施的适用人群,需关注后续进展。
核心结论
- KDIGO 2020指南旨在通过整合新治疗选择与现有管理策略,优化糖尿病合并CKD患者的临床照护。
研究设计与样本
- 本文为对KDIGO 2020年糖尿病合并CKD管理指南的解读,非原始研究。
主要发现
- 大型临床试验证据表明SGLT2抑制剂和GLP-1受体激动剂等新治疗可提供器官保护,而不仅是血糖管理。
- 指南发布后新进展为新干预措施提供了新机会并拓宽了目标人群。
关键数值与推荐
- 指南聚焦综合照护、血糖监测与目标、降糖治疗及指南发布后的新进展。
临床怎么用
- 临床应将SGLT2抑制剂和GLP-1受体激动剂等器官保护治疗整合入糖尿病合并CKD患者的综合管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Diabetes Management in Chronic Kidney Disease from 2020 comes at an opportune time when progress in diabetes technology and therapeutics offers new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. Management of haemoglobin A1c is important in diabetes, but an enlarging base of evidence from large clinical trials has demonstrated important new treatments offering organ protection and not just glucose management, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. It is the ambition that the guideline can help to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies based on high-quality evidence. Here, the focus has been on comprehensive care of patients with diabetes and CKD, glycaemic monitoring and targets, antihyperglycaemic therapies in patients with diabetes and CKD, and new developments since the guideline was published offering new opportunities and a wider target population for the new interventions.
引用
- Rossing P. HbA1c and beyond. Nephrol Dial Transplant. 2023. PMID: 34383945. doi:10.1093/ndt/gfab243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。